[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607719":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":31,"locations":40,"responsibleParty":58,"collaborators":11,"id":60,"slug":11,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":11,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":11,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":11,"overallStatus":43,"whyStopped":11,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Rohto Pharmaceutical Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Mesenchymal stem cell","EXPERIMENTAL",null,[13],"Biological: Mesenchymal stem cell",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Biological: Placebo",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"BIOLOGICAL","ADR-002K administration",[9],{"type":21,"name":15,"description":15,"armGroupLabels":25,"otherNames":11},[15],[27],{"name":28,"affiliation":29,"role":30},"Shigeru Miyagawa, profesor","Osaka University","PRINCIPAL_INVESTIGATOR",[32,37],{"name":33,"role":34,"phone":35,"phoneExt":11,"email":36},"Sumito Okawa, Study Director","CONTACT","81-3-6832-6014","R-regenerative_medicine@rohto.co.jp",{"name":38,"role":34,"phone":39,"phoneExt":11,"email":36},"Toshiyuki Osawa","81-6-6447-8610",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"The University of Osaka Hospital","RECRUITING","Osaka","Suita","5650871","Japan",{"type":49,"coordinates":50},"Point",[51,52],135.50107,34.69379,{"lat":52,"lon":51},[55],{"name":11,"role":34,"phone":56,"phoneExt":11,"email":57},"081-6-6879-5111","jim-chiken@hp-crc.med.osaka-u.ac.jp",{"type":59,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100607719",false,"NCT07192211","Exploratory Study of ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Undergo CABG","Exploratory Study of ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Undergo Coronary Artery Bypass Surgery","Inclusion Criteria:\n\n1. Patients clinically diagnosed with chronic heart failure due to ischemic heart disease who undergo CABG\n2. Patients with an LVEF of less than 40% as determined by the cardiac ultrasound at the screening examination.\n3. Others\n\nExclusion Criteria:\n\n1. Patients who have a combination of cardiovascular disease such as severe organic valvular disease.\n2. Patients who have developed acute coronary syndrome within 3 months prior to obtaining consent.\n3. Others","ALL","18 Years","80 Years",{"count":70,"type":71},50,"ESTIMATED","INTERVENTIONAL",[74],"PHASE2","ADR-002K is administered to heart failure patients with ischemic heart disease who undergo coronary artery bypass surgery (CABG) to investigate its efficacy and safety.",[77],"Ischemic Heart Disease","2026-06-07",{"date":80,"type":81},"2026-06-09","ACTUAL",{"date":83,"type":81},"2026-04-28",{"date":85,"type":71},"2029-03-31",{"name":5,"class":6},1]